

**CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP**  
**VIRTUAL MEETING RECAP FOR**  
**AUGUST 5, 2026**

**This was an open meeting with no guest speaker and there were 26 members in attendance. We also welcomed 1 new member.**

**THE NEXT VIRTUAL SUPPORT GROUP MEETING WILL BE HELD ON WEDNESDAY, SEPTEMBER 9 @ 6:30 PM EDT AND NOT SEPTEMBER 2**

**Upcoming Events:**

- International Myeloma Foundation
  - <https://www.myeloma.org/>
  - Multiple Myeloma Care Partner Support Group (virtual)
    - August 13 @ 7:00 pm EDT
  - Las Voces de Mieloma
    - August 18 @ 1:00 pm EDT
  - Living Solo and Strong with Myeloma
    - Sept 1 @ 6:00 pm EDT
  - Living Well with High Risk Multiple Myeloma
    - Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm EDT. Next meeting August 17 @ 7:00 pm EDT

- MGUS 4 US
  - Please email Emily Gordon at [erg2172@cumc.columbia.edu](mailto:erg2172@cumc.columbia.edu) if you have questions or for meeting information
- Smolder Bolder
  - Sept 8 @ 7:30-9:30 pm EDT
- Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)
  - August 11 @ 8:00-9:00 pm EDT
- The Veterans with Myeloma Special Interest Group (Virtual)
  - Meets the 4th Wednesday of the month. For more information or to sign up for group emails visit
    - <https://www.myeloma.org/support-group/veterans-myeloma-special-interest-group>
  - August 25 @ 5:00 pm EDT
- Myeloma in the Middle
  - August 18 @ 7:30 pm EDT
- Iceland Cycling Expedition Virtual Challenge
  - Event Date: 08/01/2026 - 12:00am EST thru Aug, 08/31/2026 - 12:00am EST
  - This August, participants of the International Myeloma Foundation's Iceland Cycling Expedition will cycle across Iceland to raise awareness and funds to improve lives and accelerate the cure for

myeloma. Join them through the Iceland Cycling Expedition Virtual Challenge

- Ride through your neighborhood, on your Peloton, at your local gym or wherever you enjoy cycling while following the journey of our cyclists in Iceland.
- Participation is free, and there is no fundraising minimum.

Choose your own goal and ride at your own pace while supporting the International Myeloma Foundation's mission to improve lives and accelerate the cure

- Raise \$50 and receive an IMF hat.
- Raise \$500 and earn a Limited-Edition Iceland Cycling Expedition 2026 Jersey.
- Together, we ride with one purpose: a world without myeloma.
- Register Here:  
<https://fundraise.myeloma.org/event/2026-iceland-cycling-expedition/e762163>

- Beyond the Data: A Patient & Care Partner Conversation on Myeloma Research from ASCO
  - Aug 18 @ 6:00 pm EDT
- What's Next? - Managing Myeloma at Relapse
  - Aug 24 @ 6:00 pm EDT
- Massey Community Cancer Forum: Focus on Myeloma (Virtual)
  - Aug 25 @ 1:00 pm EDT
- Patient and Family Seminar 2026
  - Short Hills, NJ
  - Oct 2-3
  - Beginning Oct 2 @ 12:00 pm EDT

- Seating is limited

## **Triage Cancer**

<https://tragecancer.org/>

- Events
  - Webinars
    - Ready to Return: Understand Your Rights When Going Back to Work
      - August 26 @ 1:00 pm EDT

## **Myeloma News:**

- Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA
- FDA Accepts New Drug Application for Mezigdomide in Combination with Carfilzomib and Dexamethasone as Treatment for Relapsed/Refractory Myeloma
- Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy
- Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
- Positive Topline Results from the Phase 3 MonumenTAL-6 Trial: Teclistamab Plus Talquetamab, Talquetamab Plus Pomalidomide Improved PFS and OS vs Standard of Care in RRMM
- Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma

- Mezigdomide Triplet Cuts Progression Risk by 52% in Relapsed Myeloma
- CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma
- ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment

### **Support Group News:**

- 14<sup>th</sup> Annual Miracles for Myeloma 5K Run/Walk Hybrid Edition
  - September 19, 2026 @ Oak Ridge Park, Clark NJ
  - <https://fundraise.myeloma.org/event/2026-miracles-for-myeloma-virtual-in-person-5k-run-walk-clark-nj/e772793>
  - “Path to \$1,000,000 in monies raised for research
  - 13 Brian D. Novis Research Grants funded
  - \$23K raised to date, 12 Teams started, and the Central New Jersey Support Group Team has 7 team members to date, and over \$1000 raised
  - Race time @ 9:30 am
  - Same day registration begins @7:30 am

Come and join us! Be part of the Miracle! You can also donate to the race, donate to a team, purchase a Remembrance Path Placard, and since it is a hybrid race, you can participate where you live as well.

- Patriots Ballgame
  - On July 29<sup>th</sup>, members of the group attended a Somerset Patriots ballgame. For a week, we all watched the weather forecast, as it was supposed to be stormy for the game one day and clear on another. Well, it could not have turned out better! To top it off the Patriots won!!

- AKTIV Against Cancer (pronounced “active”)
  - AKTIV Against Cancer is an exercise program free for eligible cancer patients. The AKTIV Center is located at the Summit Health Complex, Diamond Hill Road, Berkeley Heights
  - They offer Oncology focused personalized strength training
  - Personalized aerobic conditioning
  - Therapeutic yoga
  - Supervised walking groups, both indoors and outdoors
  - <https://www.sh-cares.org/how-we-help/cancer-comfort-project/aktiv-center/>
- One of our members asked if anyone was familiar with Zometa being used as a “once and done” bridging therapy after stopping Xgeva (Denosumab). We were not familiar, and by the group’s reaction, no one else seemed to be. Randy and Sandy sent us information on this topic from Dr. Durie, and I was able to find some updated information. You may be interested in discussing this topic with your health care team.
  - Is it Safe to Stop Denosumab (Xgeva)? (Dr. Durie, 2019)
    - <https://www.myeloma.org/videos/it-safe-stop-xgeva-denosumab>
  - Denosumab discontinuation and fracture risk: getting the balance right (Wiley On-line Library, 2026)
    - <https://onlinelibrary.wiley.com/doi/10.1111/imj.70519>
- There has been a lot of discussion lately about CELmods and their role in MM treatment. Here is some information...
  - Understanding CELMoDs (Cereblon E3 Ligase Modulatory Drugs)

- <https://www.myeloma.org/resource-library/understanding-celmods>
- Upcoming Speakers
  - Sept 9 - Adaptive Biotech – ClonoSEQ MRD Blood Test
  - Oct 7 – Tom Whitehead, Co-Founder of the Emily Whitehead Foundation and father of Emily Whitehead
    - Emily was the first person to receive the experimental treatment founded by Dr. Carl June at UPenn, CAR t-cell therapy, when she was 7 yrs old, back in 2012. Tom will speak to the group about his experience and the foundation. Emily is now 21 years old and remains cancer free. She has paved the way for so many...
    - <https://www.emilywhiteheadfoundation.org/our-cause/>
  - Any suggestions for speakers for 2027? Here are our thoughts...
    - We spoke to Dr. Urvi Shah at the Support Group Leaders Summit, and she said either someone from her staff or herself would speak to the group in 2027
    - A Nephrologist
    - Someone to speak about Peripheral Neuropathy
    - A Myeloma Specialist

# CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

## AUGUST 5, 2026 VIRTUAL MEETING RECAP

### INFORMATIONAL MYELOMA LINKS

#### International Myeloma Foundation

<https://www.myeloma.org/>

#### Resources and Support

- Find a Support Group
- **Multiple Myeloma Care Partner Support Group (virtual)**
  - **August 13 @7:00 pm EDT**
- **Las Voces de Mieloma**
  - **August 18 @ 1:00 pm EDT**
- **Living Solo and Strong with Myeloma**
  - **Sept 1 @ 6:00 pm EDT**
- **Living Well with High Risk Multiple Myeloma**
  - **Meets 3rd Thursday of each month, alternating daytime/evening hours. Odd months, 12:00 pm ET, even months 7:00 pm EDT. Next meeting August 17 @ 7:00 pm EDT**
- **MGUS 4 US**
  - **Please email Emily Gordon at [erg2172@cumc.columbia.edu](mailto:erg2172@cumc.columbia.edu) if you have questions or for meeting information**
- **Smolder Bolder**
  - **Sept 8 @ 7:30-9:30 pm EDT**

- **Strength Through Inspiration: A Virtual Support Group for Multiple Myeloma Patients & Caregivers who have Young Children (every other month)**
  - **August 11 @ 8:00-9:00 pm EDT**
- **The Veterans with Myeloma Special Interest Group (Virtual)**
  - **Meets the 4th Wednesday of the month. For more information or to sign up for group emails visit**
    - <https://www.myeloma.org/support-group/veterans-myeloma-special-interest-group>
  - **August 25 @ 5:00 pm EDT**
- **Myeloma in the Middle**
  - **August 18 @ 7:30 pm EDT**

Contact the Info Line

<https://www.myeloma.org/infoline>

Care Partner Resources

Find a Clinical Trial

Myeloma Knowledge Platform

Patient /Family Seminars

Community Workshops

Weekly Newsletter

Mind, Body, Wellness

Patient Perspective at ASH

Diversity, Equity, and Inclusion

## External Resources

Drug Reimbursement and Co-Pay Assistance Resources

Financial Resources

Government Resources

Counseling and Support Resources

Housing and Travel Resources

International Support

Legal Resources

Pain Management Resources

Transplant Resources

Other Cancer Resources

## News

- [Sarclisa \(isatuximab-irfc\) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA](#)
- [FDA Accepts New Drug Application for Mezigdomide in Combination with Carfilzomib and Dexamethasone as Treatment for Relapsed/Refractory Myeloma](#)
- [Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy](#)
- [FAQs on the FDA Approval of Sarclisa SC \(isatuximab-irfc\) for Myeloma Indications](#)
- [Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act](#)

- Positive Topline Results from the Phase 3 MonumenTAL-6 Trial: Teclistamab Plus Talquetamab, Talquetamab Plus Pomalidomide Improved PFS and OS vs Standard of Care in RRMM

## Events

- Iceland Cycling Expedition Virtual Challenge
  - Event Date: 08/01/2026 - 12:00am EST thru Aug, 08/31/2026 - 12:00am EST
  - This August, participants of the International Myeloma Foundation's Iceland Cycling Expedition will cycle across Iceland to raise awareness and funds to improve lives and accelerate the cure for myeloma. Join them through the Iceland Cycling Expedition Virtual Challenge
  - Ride through your neighborhood, on your Peloton, at your local gym or wherever you enjoy cycling while following the journey of our cyclists in Iceland.
  - Participation is free, and there is no fundraising minimum. Choose your own goal and ride at your own pace while supporting the International Myeloma Foundation's mission to improve lives and accelerate the cure
  - Raise \$50 and receive an IMF hat.
  - Raise \$500 and earn a Limited-Edition Iceland Cycling Expedition 2026 Jersey.
  - Together, we ride with one purpose: a world without myeloma.
  - Register Here:  
<https://fundraise.myeloma.org/event/2026-iceland-cycling-expedition/e762163>

- Beyond the Data: A Patient & Care Partner Conversation on Myeloma Research from ASCO
  - Aug 18 @ 6:00 pm EDT
- What's Next? - Managing Myeloma at Relapse
  - Aug 24 @ 6:00 pm EDT
- Massey Community Cancer Forum: Focus on Myeloma (Virtual)
  - Aug 25 @ 1:00 pm EDT
- Patient and Family Seminar 2026
  - Short Hills, NJ
  - Oct 2-3
  - Beginning Oct 2 @ 12:00 pm EDT
  - Seating is limited

## Blogs

- Navigating Insurance and Medical Bills
- Top Takeaways from The IMF Conference Series: Highlights from ASCO, IMWG, and EHA 2026
- Jim Omel, MD: When the Doctor Becomes the Patient
- June 2026 ASCO and EHA: Top 10 Research Abstracts and July 2026: What's New in Myeloma?
- Updated FAQs on Newly Diagnosed Multiple Myeloma for 2026 with Dr. S. Vincent Rajkumar

## Videos (\*\*New Page Design\*\*)

- Myeloma Made Simple
- Myeloma in a Minute
- Emerging Therapies
- Symptom Management
- Facebook Live

- Living Well with Myeloma
- Myeloma University
- Community Workshop
- Featured Videos
- Recommended for you (create an account)
- Emerging Therapies
- Living Well With Myeloma
- Community Workshops

### What is Multiple Myeloma

- Newly Diagnosed
- Tests and Staging
- Treatment

### Publications and Broadcasts

- IMF Publications
- IMF Broadcasts
- Healthcare Professional Resource

### Resources and Support

- IMF Support Network
- Diversity, Equity, Inclusion
- **External Resources**
  - **Drug Reimbursement Information and Assistance**
  - **Financial Assistance**
  - **Government Assistance**
  - **Guidance and Support**
  - **Housing and Travel Assistance**
  - **International Support**
  - **Legal Assistance**
  - **Pain Management**
  - **Transplant Resources**
  - **Other Cancer Resources**

- Veterans Against Myeloma
  - <https://www.myeloma.org/veterans-against-myeloma>
- [M-Power](#)
- **IMF's Infoline**
  - <https://www.myeloma.org/infoline>

### **800-452 CURE (2873)**

- **Email: [infoline@myeloma.org](mailto:infoline@myeloma.org)**
- IMF Medical Research
  - Black Swan Research Initiative
  - International Myeloma Working Group
  - Asian Myeloma Network
  - Road to the Cure
- Nurse Leadership Board
  - Nurse Leadership Board Members
  - Nurse Leadership Board Publications
  - Nursing Resources

### **Multiple Myeloma Research Foundation**

<https://themmrf.org/>

- Blogs
  - What's Changing in Multiple Myeloma? Key Clinical Takeaways from ASCO and EHA 2026
  - Hearn Jay Cho, MD, PhD on the Evolution and Future of Myeloma Care

- 15 Years, 1,143 Patients, Hundreds of Breakthroughs: How CoMMpass Transformed What We Know About Myeloma
- How to Make Smarter Decisions at Every Step of Your Myeloma Journey
- Highlights from the MMRF's Meeting on AI and Data in Multiple Myeloma
- MMRF Virtual Lab® Poised to Transform Data Sharing for Multiple Myeloma Research
- Horizon One Clinical Trial Beats Enrollment Goals, Plans New Treatment Arm
- A New Way to Receive Sarclisa (Isatuximab): What the Subcutaneous On-Body Delivery System Means for Patients
- Understanding Multiple Myeloma
- Navigating Diagnosis & Treatment
- Finding Support
  - Patient Navigation Center
  - Myeloma Mentors
  - Education Resource Hub
    - Videos
    - New Myeloma Downloadable Fast Fact Cards
    - MMRF Patient Toolkit
    - Events
- Finding a Cure
- Get Involved

- Resources on Demand

- In Print

## Videos

- Finding a Cure
- Patient Navigation Center
  - **Monday–Friday, 9 AM–7 PM ET 1-888-841-MMRF (6673)**
  - Information and Resources
  - Perspective on Treatments
  - Support
  - Get on the Right Path for You
    - Right Team
    - Right Tests
    - Right Treatment
  - Meet the Patient Navigators
  - Connect with a Myeloma Mentor

## Myeloma Matters – MMRF Podcast

<https://www.youtube.com/playlist?list=PL6YqSpftWXYZht7lBSsLFkyvKsWAZSGq4>

- Great Topics!

## HeathTree Foundation for Multiple Myeloma

<https://healthtree.org/>

## Education

- News Articles

- Conference Updates
- Educational Resources
  - University
  - Patient Guides
  - Expert Webinars
    - Many upcoming interesting webinars
  - Learn from Specialists
    - Find a Specialist
      - Podcasts
      - HealthTree Roundtables
  - Additional Resources
    - Myeloma 101
    - Newly Diagnosed Guide
    - Financial Resources
    - Medications
    - Understanding Labs
- Community
  - Join the Conversation
    - Connect
      - Join a social platform specifically for Multiple Myeloma
  - Patient-to-Patient Connections
    - Coach
      - Find a personal coach to help navigate your Myeloma
    - Moves
      - Tackle challenges and crush your fitness goals together
  - Community Events
    - All Events

- Join Educational Groups
    - Attend Topic Based Events to Further Your Cancer Education
  - Community Support Groups
- Black and Hispanic Support
  - Black Myeloma Health
  - Resources in Spanish
- Cure Hub
  - Join Cure Hub
  - Track Your Disease
    - Connect Medical Records
    - See Tracked Labs
    - Record Side Effects
  - Find the Best Treatments
    - Treatment Options
    - Clinical Trial Finder
    - Twin Machine
  - Find Support
    - Find Side Effect Solutions
    - My Journal
      - Journal Your Multiple Myeloma Story
    - Register for Cure Tour

## **HealthTree University – YouTube**

<https://www.youtube.com/c/HealthTreeUniversity>

## **SparkCures**

<https://sparkcures.com/>

- Myeloma Support...Personalized.
- “Whether it's clinical trials, treatments or finding a myeloma specialist, we help you understand your myeloma options”
- 888-828-2206
- Now featuring trial options for MDS (Myelodysplastic Syndromes) and NTRK Gene Fusion Cancers

## **Myeloma Central**

<https://www.myelomacentral.com/>

- Standing in the Gaap
  - Resources for African Americans
- Multiple Myeloma Resources for Nurses

## **Cure**

<https://www.curetoday.com/tumor/myeloma>

- Latest News
  - Mezigdomide Triplet Cuts Progression Risk by 52% in Relapsed Myeloma
- Video Series
- Latest Videos
- Shorts
- Podcasts
- More News

## **Cure – Cancer Horizons**

<https://www.curetoday.com/cancer-horizons>

- Choose “Myeloma”
  - Understanding the Use of Bispecific Antibodies in Multiple Myeloma
  - Communication is Key When Transitioning Multiple Myeloma Care
  - What Is CAR-T Cell Therapy, and What Can Patients With Cancer Expect?

## **OncLive/OncLive Videos**

<https://www.onclive.com/clinical/multiple-myeloma>

- Latest News
  - Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
- Video Series
- Latest Videos
- Shorts
- Podcasts
  - FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS
- More News
  - Many great articles

## Multiple Myeloma Hub

<https://multiplemyelomahub.com/>

- News
  - The phase II ERASMM trial: Elranatamab for high-risk smoldering MM
  - MonumenTAL-3: Talquetamab-based combinations for RRMM
  - ctDNA-NGS for peripheral blood MRD monitoring in NDMM
  - Non-ICANS neurological events with cilta-cel in RRMM: Review of the CARTITUDE trials
- Recent Content
  - Final analysis of the phase I DREAMM-9 trial: BVRd for TI NDMM
  - FDA accepts new drug application for mezigdomide + Kd for RRMM
  - MajesTEC-3: Subanalysis by cytogenetic and functional risk
  - CEVOLUTION: Phase III trial of cevostamab + Pd for RRMM
- Most Read
  - Strategies for managing belantamab mafodotin-associated ocular toxicities
  - Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM
- Multiple Myeloma Hub Symposia

- Steering Committee Meetings
- Drug Updates
  - FDA accepts new drug application for mezigdomide, an oral CELMoD, in combination with carfilzomib + dexamethasone for the treatment of RRMM based on results from the phase III SUCCESSOR-2 trial

### **Multiple Myeloma Hub Podcast**

<https://podcasts.apple.com/us/podcast/multiple-myeloma-hub/id1513939744>

- Strategies for managing belantamab mafodotin-associated ocular toxicities
- Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM
- EHA2026 | What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?
- EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses

### **Patient Power**

<https://www.patientpower.info/community/multiple-myeloma>

### **American Society of Hematology (ASH)**

<https://www.hematology.org/>

## **The ASCO Post**

<https://ascopost.com/search-results/?q=myeloma>

- AACR Cancer Disparities Progress Report: Trends Show Mortality Rates Improve But Inequity in Care Remains
- Second Primary Malignancies After T-Cell–Engaging Bispecific Antibody Therapy
- FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
- ENDURANCE Trial in Newly Diagnosed Myeloma: No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment

## **ASCO Daily News**

<https://dailynews.ascopubs.org/action/doSearch?AllField=myeloma>

## **ASCO Daily News Podcasts**

<https://dailynews.ascopubs.org/podcasts>

## **Blood**

<https://ashpublications.org/blood/issue-covers>

- The rapidly evolving BCMA landscape in multiple myeloma

- <https://ashpublications.org/blood/article/148/2/151/569454/The-rapidly-evolving-BCMA-landscape-in-multiple>
- Two birds with one stone: faster, fitter CAR T cells
  - <https://ashpublications.org/blood/article/148/6/644/569918/Two-birds-with-one-stone-faster-fitter-CAR-T-cells>

### **Blood Cancer Talks – Podcast**

<https://podcasts.apple.com/us/podcast/blood-cancer-talks/id1633724992>

### **The Patient Story**

<https://thepatientstory.com/patient-stories/multiple-myeloma/>

### **Targeted Oncology**

<https://www.targetedonc.com/clinical/multiple-myeloma-rc>

### **Latest News**

- Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
- Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
- **Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma**
- Considering the Applications of On-Body Injector for Myeloma in Community Practice

- Video Series
- Latest Videos
- Shorts
- Podcasts
- More News
  - New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
  - Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
  - Implementing a Bispecific Antibody Program in Community Oncology: Insights From the American Oncology Network
  - FDA Approves Subcutaneous Isatuximab for Multiple Myeloma
  - CARTITUDE-4 Data, IMWG Guideline Make the Case for Second-Line CAR T in Myeloma
  - FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
  - Analyses Support Integrating MRD and Genomic Features in Prognosis of Multiple Myeloma

## **Cancernetwork**

<https://www.cancernetwork.com/>

- “Cancer Focus – choose myeloma”
- Latest News
  - Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era

- Teclistamab Combos Improve PFS, OS in Relapsed/Refractory Multiple Myeloma
- Cevostamab Shows Durable Responses in Relapsed/Refractory Multiple Myeloma
- How Effective is Fixed-Duration Cevostamab in Multiple Myeloma?
- The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
- Video Series
- Video Interviews
- Shorts
  - Using Bispecific Antibodies as Definitive Therapy in Multiple Myeloma
  - CELMoDs Have “a Lot of Potential” in Multiple Myeloma Treatment Landscape
- Podcasts
- More news
  - How Are CELMoDs Reshaping Treatment in Multiple Myeloma?
  - FDA Approves Subcutaneous Isatuximab in Multiple Myeloma
  - FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma
  - OS Does Not Improve With Continuous vs Fixed Lenalidomide Dosing in NDMM

## **Patient Empowerment Network**

<https://powerfulpatients.org/cancer-diagnosis/multiple-myeloma/>

## **Smart Patients**

<https://www.smartpatients.com/site>

## **HemOnc Pulse (Podcast)**

<https://www.bloodcancerstoday.com/category/hemonc-pulse>

- Great podcasts on Myeloma

## **Blood & Marrow Transplant Information Network**

<https://bmtinfonet.org/>

- “Blood & Marrow Transplant Information Network (BMT InfoNet) is not-for-profit 501 (c) 3 organization dedicated to providing transplant and CAR T-cell therapy recipients and their loved ones with emotional support and high quality, easy-to-understand information about bone marrow, peripheral blood stem cell and cord blood transplant, and CAR T-cell therapy.”

## **Blood Cancer United (formerly LLS)**

<https://bloodcancerunited.org/>

- Hematology Horizons Vlog Series  
<https://bloodcancerunited.org/resources/educational-resources/video/hematology-horizons-vlog-series>

- Blood Cancer Close to Home
- Navigating Loss and Grief After A Cancer Diagnosis
- Advances in CAR t-cell Therapy
- The Bloodline with Blood Cancer United Podcast
  - <https://thebloodline.org/episodes/>
    - Advocating for Yourself: Insurance, Finances, and Your Rights
    - Making Your Voice Count: The Power of Patient Advocacy
- Blood Cancer United Vodcasts
  - <https://bloodcancerunited.org/resources/educational-resources/video/bloodline-breakthroughs-innovations-inspiration>
- Blood Cancer United Video and Webcasts
  - <https://bloodcancerunited.org/resources/educational-resources/webcasts-videos>
    - Bispecific antibodies explained for blood cancers

### **Weekly Online Chat:**

- **Veterans Living with Blood Cancer**
  - **Every Tuesday Evening @ 8:00-10:00pm EDT**
  - **Online Chat for Caregivers:**
- **Every Thursday Evening @ 8:00-10:00 pm EDT**
- **Online Chat Living with Myeloma:**
  - **Every Monday Evening @ 8:00-10:00 pm EDT**

- **Online Chat for Patients and Caregivers - Banding Together: Feeling Good Fridays**
  - **Every Friday @ 1:00-3:00 pm EDT**

<https://bloodcancerunited.org/resources/patients/online-chats>

- About Us
  - About Blood Cancer United
  - Featured Programs
  - Partners and Suppliers
  - Stories and News
- Financial Assistance
  - Financial Support
  - Additional Financial Assistance
  - Claims
- Local Groups
  - Find your Region
- Blood Cancers
  - Types of Blood Cancer
- Navigating Your Care
  - Adults
  - Young Adults
  - Children and Teens
- Resources
  - Patient Resources
  - Caregiver Resources
  - Healthcare and Professional Resources
  - Educational Resources
  - Support Resources
    - Blood Cancer Information Specialist

- 1-800-955-4572
  - Clinical Trial Nurse Navigators
  - Registered Dietitian
- Newsroom

## **Oncology Nursing News**

[https://www.oncnursingnews.com/search?oncnurse\\_sanity\\_data%5Bquery%5D=myeloma](https://www.oncnursingnews.com/search?oncnurse_sanity_data%5Bquery%5D=myeloma)

- Latest News
  - FDA Approves Subcutaneous Isatuximab-irfc for Multiple Myeloma
  - Multiple Myeloma Care: Innovative Nursing Strategies and Patient Support
  - Optimizing Multiple Myeloma Care: Insights From a Nursing Expert
- Video Series
- Video Interviews
- Podcasts
- More News

## **VJHemonc (Video Journal of Oncology)**

<https://www.vjhemonc.com/subject/multiple-myeloma/>

- The Multiple Myeloma Channel (Great information)

- Latest Videos
- The Myeloma Sessions
- Conferences
- Topics
- Features
- Podcasts

## **Triage Cancer**

<https://trriagecancer.org/>

- Events
  - **Webinars**
    - **Ready to Return: Understand Your Rights When Going Back to Work**
      - **August 26 @ 1:00 pm EDT**
- Resources
- Materials
- Support

## **IMSound (International Myeloma Society Audio Short Series)**

<https://www.myelomasociety.org/imsound/>

- “IMSound, the latest audio series from the International Myeloma Society! Each episode brings insights from top experts on crucial issues in the myeloma community”

## **Oncology Central**

<https://www.oncology-central.com/?s=myeloma>

- Interesting Articles

## **Blood Cancers Today**

<https://www.bloodcancerstoday.com/>

- Redefining Age: The Changing Landscape of Hematologic Malignancy Treatments in Older Adults
- Impact of Disease Biology in Patients with Relapsed/Refractory Multiple Myeloma Following CAR-T Cell Therapy
- SUCCESSOR-2: Promising Results Expand Options in Refractory Multiple Myeloma (Video – Dr. Richardson)
- Plus many good articles!

## **Hemonc Pulse – Podcast**

<https://www.bloodcancerstoday.com/category/hemonc-pulse>

- Taking Bispecific Antibodies Outpatient: Lessons From the Front Lines

- Community-Based CAR-T Therapy: Expanding Access, Navigating Challenges

X

- Dr. Henry Fung – He posts the bests MM diagrams on twitter!!
  - For years, we dreamed of off-the-shelf CAR-T
    - <https://x.com/HenrychihangFu1/status/2069391113081811184?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
  - The Right Patient for Outpatient Bispecific
    - <https://x.com/HenrychihangFu1/status/2072300673769652257?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
  - TRUTHS vs MYTHS: Lenalidomide Maintenance in Multiple Myeloma
    - <https://x.com/HenrychihangFu1/status/2077720235881242689?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
  - Re-visiting del(13)q
    - <https://x.com/HenrychihangFu1/status/2078096424567275915?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
  - What can we learn from the ENDURANCE trial?
    - <https://x.com/HenrychihangFu1/status/2078456303475671289?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>
  - MonumenTAL-6 demonstrated that Tal-Tec outperformed EPd/PVd in this study population
    - <https://x.com/HenrychihangFu1/status/2080449863083278385?s=58&t=7w0ni0WXD12zMKqXp8TQjQ>

- Evolving Treatment Landscape in Second-Line and Beyond Multiple Myeloma
  - <https://oncupdates.com/video-podcasts/evolving-treatment-landscape-in-second-line-and-beyond-multiple-myeloma/>
- American Cancer Society
  - Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation
    - <https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70478>
- J&J
  - **TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma**
    - <https://www.jnj.com/media-center/press-releases/tecvayli-talvey-reduced-the-risk-of-disease-progression-or-death-by-89-and-the-risk-of-death-by-62-in-earlier-line-relapsed-refractory-multiple-myeloma>
- Journal of Clinical Oncology
  - High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation
    - <https://ascopubs.org/doi/abs/10.1200/JCO-26-00236?bid=654219064&md5=f1bfa234cb0ace7aa9e6791ee49213a5&cid=DM30850>

## **The Fellow on Call Podcast**

<https://www.thefellowoncall.com/>

## **Dr. Rafael Foncesca's Substack**

<https://rafaelfonseca.substack.com/>

- Great articles and diagrams!

## **OncoDaily**

<https://oncodaily.com/hematology>

- Many articles and videos

## **New England Journal of Medicine**

<https://www.nejm.org/doi/full/10.1056/NEJMoa2600157>

- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma